Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases

Area of Science:

• Pharmacology
• Gastroenterology
• Immunology

Background:

• Free Fatty Acid Receptors (FFARs) are G protein-coupled receptors activated by various fatty acids.
• FFARs are recognized as therapeutic targets for metabolic and inflammatory conditions, including asthma and type 2 diabetes.
• Emerging evidence highlights the role of FFARs in modulating inflammatory processes.

Purpose of the Study:

• To review current knowledge on FFARs and their relevance to inflammatory bowel diseases (IBD).
• To explore the potential of FFARs as therapeutic targets for IBD treatment.
• To discuss future research directions in FFARs for IBD.

Main Methods:

• Literature review of studies on FFARs, fatty acids, and inflammation.
• Analysis of FFAR subtypes (FFAR1-4) and their specific fatty acid activators.
• Discussion of FFARs' mechanisms in inflammation, particularly neutrophil inhibition.

Main Results:

• FFAR1 and FFAR4 activation by long/medium-chain fatty acids reduces inflammation.
• FFAR2 activation by short-chain fatty acids alleviates inflammation, notably via neutrophil inhibition.
• FFAR3 activation by short-chain fatty acids is also noted, though its anti-inflammatory role is less defined.

Conclusions:

• All FFARs are proposed as potential therapeutic targets for inflammatory bowel diseases (IBD).
• Targeting FFARs offers a promising strategy for managing IBD.
• Further research is warranted to fully elucidate FFAR roles and optimize therapeutic strategies for IBD.